Group 1 - On February 2, Huaxi Bio's stock rose by 5.24%, with a trading volume of 562 million yuan [1] - The financing data shows that on the same day, Huaxi Bio had a financing purchase amount of 68.0048 million yuan and a net financing purchase of 3.4537 million yuan [1] - As of February 2, the total balance of margin trading for Huaxi Bio was 554 million yuan, with a financing balance of 550 million yuan, accounting for 2.42% of the circulating market value [1] Group 2 - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, operates in the field of microbial fermentation and cross-linking technology, focusing on bioactive materials for health [2] - The company's revenue composition includes 40.34% from skin science innovation, 29.76% from medical terminal products, and 27.70% from raw materials [2] - For the period from January to September 2025, Huaxi Bio reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% year-on-year [2] Group 3 - Since its A-share listing, Huaxi Bio has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed in the last three years [3] - As of September 30, 2025, major shareholders of Huaxi Bio have seen a reduction in holdings, with the top ten circulating shareholders decreasing their shares [3]

Core Viewpoint - Huaxi Bio's stock has experienced a decline of 8.13% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the company's performance and market perception [1][2]. Company Overview - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, is located in Jinan, Shandong Province. The company specializes in microbial fermentation and cross-linking technologies, developing bioactive materials that contribute to human health [1]. - The company's business model encompasses a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetics, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Bio reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Since its A-share listing, Huaxi Bio has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of November 20, 2025, Huaxi Bio had 30,100 shareholders, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per shareholder, an increase of 0.62% [2]. - The stock has seen significant net outflows of capital, with major funds selling more than they bought, indicating a cautious sentiment among investors [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders have reduced their holdings, with notable decreases in shares held by various ETFs, indicating a potential shift in investor confidence [3].

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.00% on September 23, with a current price of 54.34 CNY per share and a total market capitalization of 26.174 billion CNY [1] Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company operates in the fields of microbial fermentation and cross-linking technology, developing bioactive materials that contribute to human health [1] - The company has established a full industry chain business system, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end-users [1] Business Revenue Composition - The revenue composition of Huaxi Biological is as follows: - Skin science innovation transformation business: 40.34% - Medical terminal products: 29.76% - Raw material products: 27.70% - Others: 2.17% - Other (supplement): 0.03% [1] Stock Performance - Year-to-date, Huaxi Biological's stock price has increased by 6.70%, but it has seen a decline of 7.00% over the last five trading days and 6.60% over the last twenty days [1] Financial Performance - For the first half of 2025, Huaxi Biological reported a revenue of 2.261 billion CNY, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million CNY, down 35.38% year-on-year [2] Shareholder Information - As of July 31, the number of shareholders of Huaxi Biological was 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2] Dividend Distribution - Since its A-share listing, Huaxi Biological has distributed a total of 1.138 billion CNY in dividends, with 528 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, major shareholders include: - Huaxia SSE Sci-Tech Innovation Board 50 ETF (588000) - 10.6429 million shares, down 244,800 shares - E Fund SSE Sci-Tech Innovation Board 50 ETF (588080) - 7.9777 million shares, up 227,800 shares - Huabao CSI Medical ETF (512170) - 6.4329 million shares, newly entered - Hong Kong Central Clearing Limited - 5.7990 million shares, up 1.3124 million shares [3]

Company Overview - Huaxi Biological Technology Co., Ltd. is located in Jinan, Shandong Province, established on January 3, 2000, and listed on November 6, 2019. The company specializes in microbial fermentation and cross-linking technology platforms, developing bioactive materials that benefit human health. It has established a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [2]. Financial Performance - As of July 31, the number of Huaxi Biological shareholders reached 32,500, an increase of 1.78% from the previous period. The average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - For the first half of 2025, Huaxi Biological reported operating revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%. The net profit attributable to the parent company was 221 million yuan, down 35.38% year-on-year [2]. Stock Performance - Huaxi Biological's stock price has increased by 14.59% year-to-date, with a 1.81% rise over the last five trading days, a 13.65% increase over the last 20 days, and a 6.69% increase over the last 60 days [2]. - On September 1, the stock price rose by 2.03%, reaching 58.36 yuan per share, with a trading volume of 246 million yuan and a turnover rate of 0.89%. The total market capitalization stood at 28.111 billion yuan [1]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included various ETFs, with notable changes in holdings. For instance, Huaxia SSE Sci-Tech Innovation Board 50 ETF held 10.6429 million shares, down 244,800 shares from the previous period. Meanwhile, the E Fund SSE Sci-Tech Innovation Board 50 ETF increased its holdings by 227,800 shares to 7.9777 million shares [3].